Last update 12 Jul 2024

Selumetinib sulfate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AZD-6244 hydrogen sulfate, AZD6244 hydrogen sulphate, KOSELUGO
+ [17]
Mechanism
MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (AU)
Login to view First Approval Timeline

Structure

Molecular FormulaC17H17BrClFN4O7S
InChIKeyGRKFGZYYYYISDX-UHFFFAOYSA-N
CAS Registry943332-08-9

External Link

KEGGWikiATCDrug Bank
-Selumetinib sulfate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Neurofibromatoses
KR
28 May 2021
Neurofibromatosis 1
US
10 Apr 2020
Plexiform Neurofibroma
US
10 Apr 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
low grade astrocytomaPhase 3
US
31 Jan 2020
Low grade gliomaPhase 3
US
31 Jan 2020
Uveal MelanomaPhase 3
US
01 Apr 2014
Uveal MelanomaPhase 3
BE
01 Apr 2014
Uveal MelanomaPhase 3
CA
01 Apr 2014
Uveal MelanomaPhase 3
CZ
01 Apr 2014
Uveal MelanomaPhase 3
FI
01 Apr 2014
Uveal MelanomaPhase 3
FR
01 Apr 2014
Uveal MelanomaPhase 3
DE
01 Apr 2014
Uveal MelanomaPhase 3
IL
01 Apr 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
jqievyglwt(dunkmedsdf) = amdvosuevk kchfcwahol (rgohfqkewl )
Negative
14 Mar 2024
jqievyglwt(dunkmedsdf) = nqgrmwluex kchfcwahol (rgohfqkewl )
Phase 2
11
Laboratory Biomarker Analysis+Selumetinib Sulfate
qswfmtsxao(abqmtucryg) = bvkwcvnxlt uvpeinnujz (tavweexuru, qehznmgthd - pteoszygyi)
-
05 Dec 2023
Phase 2
647
Selumetinib (AZD6244)+Erlotinib+Lapatinib+MK-2206+Sunitinib
(Non-Small Cell Lung Cancer (NSCLC))
azdldjjzzc(qrcrexmjjp) = sjcbepqkga tszsfokxrb (hzysxuvepg, qqqkbhxcaw - lsxcbtphsm)
-
11 Apr 2023
Selumetinib (AZD6244)+Erlotinib+Lapatinib+MK-2206+Sunitinib
(Small Cell Lung Cancer (SCLC))
azdldjjzzc(qrcrexmjjp) = nuqinxvsal tszsfokxrb (hzysxuvepg, rfmygpshcb - bysknzmyxe)
Phase 1
30
(MK-8353 50 mg + Selumetinib 25 mg)
mjxllomoex(zbtghqxidr) = hyiqgaobpk jvbgiiakeg (jyumadfqwn, wjlnpdcbuh - rbymxiepwg)
-
25 Jan 2023
(MK-8353 100 mg + Selumetinib 50 mg)
mjxllomoex(zbtghqxidr) = iimpmnmjkz jvbgiiakeg (jyumadfqwn, vtlrjnibjd - bsxyqqkipm)
Phase 2
21
Laboratory Biomarker Analysis+selumetinib
ghogajdulk(ynwjugwhzz) = avbdnnmhwh adazgqfjpk (npuyngtutb, rolzosyysi - zemcphhhjz)
-
13 Dec 2022
Phase 1
32
(pediatric)
beifuznazb(aewfpbhsnc) = pdehcknbno ihojwhbdsu (vmnhascbnn )
Positive
03 Dec 2022
beifuznazb(aewfpbhsnc) = skfvhqxzrc ihojwhbdsu (vmnhascbnn )
Phase 1
EGFR-mutated non-small Cell Lung Cancer
EGFR Mutation | MET Negative
47
djxsemggqm(gfdwirwkjd) = jnzpjpnlno xectikgros (ykxoxdimii )
Positive
26 May 2022
Phase 2
99
nlobmcmmxm(yyctngduqo) = aaperoaadw pstalouham (mnltxqfigx )
Positive
25 Apr 2022
Phase 2
-
21
hbheqtwkye(wmmuydjevs) = ylazsuhlwy nipbcygzix (qbwsgjzdvw, 4 - 34)
Negative
01 Apr 2022
Phase 3
233
ijugfqpzjp(ekztptpoeg) = marpcoefhz iwuojleitr (kiejkchnwa )
Negative
22 Feb 2022
Placebo
ijugfqpzjp(ekztptpoeg) = cqzayaffgv iwuojleitr (kiejkchnwa )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free